Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 14 Apr 2025
A study presented at ESCMID Global 2025 has demonstrated that an AI-powered lung ultrasound outperforms human experts by 9% in diagnosing pulmonary tuberculosis (TB).
Read Full News8 Pulmonology Headlines You Missed in Q3 2026
PROPEL will test imeroprubart, an investigational FcRn blocker, against placebo in adults with mild to severe generalized myasthenia gravis.
Here's some of what is coming soon to NeurologyLive® this week.
New analyses from the D1AMOND clinical program found that 69.8% of participants achieved a clinically meaningful reduction in tic severity within 8 weeks of ecopipam treatment, while an interim 18-month analysis showed sustained improvement without new safety signals.
Full results from the phase 2b LUMA showed that investigational BIIB122/DNL151 did not slow confirmed clinical worsening in early-stage Parkinson's disease compared with placebo.
Early phase 1 findings showed that the PROTAC LRRK2 degrader ARV-102 was associated with improvements in saccadic hypometria and changes in CSF markers of endolysosomal function, neuroinflammation, synaptic integrity, and axonal guidance in participants with Parkinson disease.
6 Nephrology Headlines You Missed in September 2026
1.
Black women have a higher risk of dying from all types of breast cancer, meta-analysis reveals
2.
Every cancer is different because of how evolution causes drug resistance and why various cancers require various treatments.
3.
Preschoolers With Cancer Have Poor Motor Skills
4.
When it comes to obesity-related cancers, where you shop for food matters
5.
Perioperative Nivolumab Boosts EFS Versus Neoadjuvant-Only Nivolumab in NSCLC
1.
Unleashing the Inner Predator: Reprogramming Macrophages to Conquer Cancer Immunotherapy
2.
From Bench to Bedside: The New Era of Lymphoma Treatment and Education
3.
Red Cell Deformability as a Target in Critical Illness
4.
Cerebrospinal Fluid Metabolite Biomarkers in Central Nervous System Tumor Monitoring: A New Frontier
5.
Tumor Mutation Signatures From Replication Stress: Mechanisms, Clinical Implications, and Emerging Therapeutic Insights
1.
International Conference on Cancer Nursing and Rehabilitation Strategies
2.
International Conference on Best Practices in Oncology, Cardiology and Critical Care
3.
International Conference on Innovations in Critical Care for Oncology and Cardiology
4.
International Symposium on Oncology, Cardiology and Critical Care Innovations
5.
International Conference on Cancer Nursing and Hematology Support
1.
Molecular Contrast: EGFR Axon 19 vs. Exon 21 Mutations - Part V
2.
Signs and Symptoms of Leukemia
3.
The Reign of the CROWN Trial and the Dawn of a New Era in Frontline Management- Further Discussion
4.
From Relapse to Remission Mapping the Treatment Journey in Adult R R B Cell ALL The Critical Goal of MRD
5.
Navigating the Complexities of Ph Negative ALL - Part III
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge